Education
About Us
Working with TipRanks
Follow Us
Replimune Group Inc (DE:7R8)
FRANKFURT:7R8
7R8 Analyst Ratings
Moderate Buy
5 Buy
3 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
7R8 Stock 12 Month Forecast
Average Price Target
€9.66
▲(33.18% Upside)
| Highest Price Target€15.62 | Average Price Target€9.66 | Lowest Price Target€2.60 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
BMO Capital
€9.54
Hold
31.63%
Upside
Upgraded
11/02/25
H.C. Wainwright
€10.41
Buy
43.59%
Upside
Upgraded
10/27/25
Replimune Group's RP1 Resubmission Boosts Approval Odds and Buy RatingValuation and Risks. We utilize a discounted cash flow (DCF)-based methodology to value Replimune shares. Our core assumptions currently comprise a 12% discount rate, a 29% effective tax rate, and an 85% probability of approval for RP1 in anti-PD1 failed melanoma patients. These parameters yield a market value of $1.1B, which translates into a $12 price target, based on an estimated 92.3M shares outstanding as of end-FY2026.
Leerink Partners
€2.6→€11.28
Buy
55.56%
Upside
Upgraded
10/22/25
Barclays
€2.6
Hold
-64.10%
Downside
Reiterated
10/21/25
Piper Sandler
€6.94→€11.28
Buy
55.56%
Upside
Upgraded
10/20/25
J.P. Morgan
€5.21→€9.54
Hold
31.63%
Upside
Upgraded
10/20/25
Wedbush
€3.47→€15.62
Buy
115.39%
Upside
Upgraded
10/20/25
Jefferies
€8.68→€6.94
Buy
-4.27%
Downside
Reiterated
08/11/25
Cantor Fitzgerald
―
Buy
―
Upgraded
07/30/25
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
BMO Capital
€9.54
Hold
31.63%
Upside
Upgraded
11/02/25
H.C. Wainwright
€10.41
Buy
43.59%
Upside
Upgraded
10/27/25
Replimune Group's RP1 Resubmission Boosts Approval Odds and Buy RatingValuation and Risks. We utilize a discounted cash flow (DCF)-based methodology to value Replimune shares. Our core assumptions currently comprise a 12% discount rate, a 29% effective tax rate, and an 85% probability of approval for RP1 in anti-PD1 failed melanoma patients. These parameters yield a market value of $1.1B, which translates into a $12 price target, based on an estimated 92.3M shares outstanding as of end-FY2026.
Leerink Partners
€2.6→€11.28
Buy
55.56%
Upside
Upgraded
10/22/25
Barclays
€2.6
Hold
-64.10%
Downside
Reiterated
10/21/25
Piper Sandler
€6.94→€11.28
Buy
55.56%
Upside
Upgraded
10/20/25
J.P. Morgan
€5.21→€9.54
Hold
31.63%
Upside
Upgraded
10/20/25
Wedbush
€3.47→€15.62
Buy
115.39%
Upside
Upgraded
10/20/25
Jefferies
€8.68→€6.94
Buy
-4.27%
Downside
Reiterated
08/11/25
Cantor Fitzgerald
―
Buy
―
Upgraded
07/30/25
Best Analysts Covering Replimune Group
1 Month
xxx
Success Rate
20/33 ratings generated profit
Average Return
+4.55%
upgraded a xxx
rating 18 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 60.61% of your transactions generating a profit, with an average return of +4.55% per trade.
3 Months
xxx
Success Rate
8/15 ratings generated profit
Average Return
-2.17%
upgraded a xxx
rating 20 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 53.33% of your transactions generating a profit, with an average return of -2.17% per trade.
1 Year
Success Rate
7/15 ratings generated profit
Average Return
+0.99%
upgraded a buy rating 20 days ago
Copying Robert Driscoll's trades and holding each position for 1 Year would result in 46.67% of your transactions generating a profit, with an average return of +0.99% per trade.
2 Years
xxx
Success Rate
3/15 ratings generated profit
Average Return
-28.35%
upgraded a xxx
rating 20 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 20.00% of your transactions generating a profit, with an average return of -28.35% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
7R8 Analyst Recommendation Trends
Rating
Jun 25
Jul 25
Aug 25
Sep 25
Oct 25
Strong Buy
11
16
12
6
3
Buy
3
4
4
1
2
Hold
1
8
11
15
9
Sell
0
1
1
2
1
Strong Sell
0
0
0
0
1
total
15
29
28
24
16
Each month's total comprises the sum of three months' worth of ratings.
7R8 Financial Forecast
7R8 Stock Forecast FAQ
What is DE:7R8’s average 12-month price target, according to analysts?
Based on analyst ratings, Replimune Group Inc’s 12-month average price target is 9.66.
What is DE:7R8’s upside potential, based on the analysts’ average price target?
Replimune Group Inc has 33.18% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is Replimune Group Inc a Buy, Sell or Hold?
Replimune Group Inc has a consensus rating of Moderate Buy, which is based on 5 buy ratings, 3 hold ratings and 0 sell ratings.
What is Replimune Group Inc’s share price target?
The average share price target for Replimune Group Inc is 9.66. This is based on 8 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €15.62 ,and the lowest forecast is €2.60. The average share price target represents 33.18% Increase from the current price of €7.25.
The highest analyst share price target is €15.62 ,and the lowest forecast is €2.60. The average share price target represents 33.18% Increase from the current price of €7.25.
What do analysts say about Replimune Group Inc?
Replimune Group Inc’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 8 Wall Streets Analysts.
How can I buy shares of Replimune Group Inc?
To buy shares of DE:7R8, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.